Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.4 million versus the consensus estimate of $5.32 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.